BioCentury This Week

EXPLORE

© 2024 PodJoint

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/c1/bd/d1/c1bdd1fe-bf57-f599-b9e0-88dfc8258785/mza_14123746456783229329.jpg/600x600bb.jpg

BioCentury This Week

BioCentury

287 episodes

1 day ago

The boom in the creation of companies that were launched in the West based on assets sourced in Asia signals China’s galloping speed of innovation. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the “NewCo Model,” who the players are, from CEOs and companies to investors; the areas of innovation the start-ups are tackling; and the evolution of the trend. (Read about the company that kicked off the trend, Arrivent, here.) The editors also assess how personnel losses a...

Show more...

All content for BioCentury This Week is the property of BioCentury and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

The boom in the creation of companies that were launched in the West based on assets sourced in Asia signals China’s galloping speed of innovation. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the “NewCo Model,” who the players are, from CEOs and companies to investors; the areas of innovation the start-ups are tackling; and the evolution of the trend. (Read about the company that kicked off the trend, Arrivent, here.) The editors also assess how personnel losses a...

Show more...

Episodes (20/287)

BioCentury This Week

Ep. 277 - Asia's NewCo Model, FDA Tipping Point, Vertex's Pain Drug

The boom in the creation of companies that were launched in the West based on assets sourced in Asia signals China’s galloping speed of innovation. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the “NewCo Model,” who the players are, from CEOs and companies to investors; the areas of innovation the start-ups are tackling; and the evolution of the trend. (Read about the company that kicked off the trend, Arrivent, here.) The editors also assess how personnel losses a...

3 days ago

24 minutes

BioCentury This Week

Ep. 276 - Precision Neuropsychiatry Spotlight With ICON's Peter Schueler

Psychiatric drug development has had major wins over the past year-and-a-half — think Karuna Pharmaceuticals' $14 billion takeout by Bristol Myers Squibb and the subsequent launch of a new schizophrenia therapy — but targeted neuropsychiatric drug development is still in its infancy. On a special edition of the BioCentury This Week podcast, BioCentury’s editors detail the promise of precision medicine in the space and break down what recent setbacks for key players mean for next steps in the ...

6 days ago

21 minutes

BioCentury This Week

Ep. 275 - Series As & Innovation. Plus: Rocky Transition at FDA, NIH

BioCentury’s analysis of the technologies behind last year’s biotech series A raisers sees progress in nanoparticles, CAR cell therapies, degraders and antibody-drug conjugates. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the trends spotted in 2024’s crop of more than 150 series A rounds — from top therapeutic areas and modalities to the leading investors funding the innovation.The editors turn to Washington for takeaways from BioCentury’s “exit interview” with Pa...

1 week ago

33 minutes

BioCentury This Week

Ep. 274 - 2025 Biotech Preview: Markets, Catalysts and AI

With political uncertainty overshadowing market sentiment going into 2025, BioCentury’s editorial team assesses the bull and bear arguments for biotech in the New Year on the BioCentury This Week podcast’s Public Markets Preview. Will continued uncertainty drive biotech sentiment in the coming months, or will the bear arguments fail to manifest, stymied by M&A and other positive factors?In the second part of the 2025 Preview, BioCentury’s editors highlight some of the key catalysts in bis...

2 weeks ago

36 minutes

BioCentury This Week

Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds

Sunshine and a stream of deals brightened the mood at this year’s J.P. Morgan Healthcare Conference, offering a pleasant counterpoint to continued pessimism over the state of the capital markets. On the latest BioCentury This Week podcast, BioCentury’s editors deliver their takeaways from biotech’s annual kick-off event from megarounds and Asian newcos to the new state of M&A and pending change at FDA. View full story: https://www.biocentury.com/article/654723 00:00 - Introduction 01:52...

3 weeks ago

22 minutes

BioCentury This Week

Ep. 272 - JPM Deal Buzz & Rep. Auchincloss’ Take on Biopharma

J&J’s $14.6 billion takeout of neurology play Intra-cellular Therapies headlined a buzzy start to the J.P. Morgan Healthcare Conference, where a flurry of deal announcements recalled the conference’s pre-pandemic days. On the latest BioCentury This Week podcast, BioCentury's editors discuss the takeout of Intra-cellular, the third 11-digit neuro M&A in the past 13 months, as well as M&A involving Idrx and GSK, and Scorpion Therapeutics and Eli Lilly. Turning to Washington, the tea...

3 weeks ago

27 minutes

BioCentury This Week

Ep. 271 - Biotech in the New Year. Plus: Beyond Biosecure

Can biotech break free of the macro factors that have buffeted the industry of late? On the first BioCentury This Week podcast of 2025, BioCentury’s editors offer their predictions for the New Year and — exploring the themes from Simone Fishburn’s latest Letter from the Editor — ask whether biotech can overcome the financing environment, policy concerns and geopolitical tension that have been hammering the industry to deliver on the meaningful strides companies have been taking to deliver inn...

1 month ago

34 minutes

BioCentury This Week

Ep. 270 - Temple’s FDA Legacy. Plus: Chinese Innovation & Novo Obesity Data

Preview: In his five decades at FDA, Robert “Bob” Temple helped revolutionize the ways medical products are developed and regulated. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin reflects on the legacy of Temple. Temple, who is retiring, crafted the modern clinical trial paradigm, created the accelerated approval pathway, and set precedents for incorporating patient perspectives in regulatory decisions. Usdin also discusses the opportunities and threats for the age...

1 month ago

34 minutes

BioCentury This Week

Bonus Content - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine

With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their case to make an attractive offer and move fast. About 40% of the M&A deals in 2023-24 were completed in less than six weeks, from approach to announcement, according to Lazard’s data. Michael Kingston and Dale Raine, global co-heads of biopharma at Lazard, joined The BioCentury Show this week to discuss the M&A outlook amid the still-prec...

1 month ago

34 minutes

BioCentury This Week

Ep. 269 - Trends in VC Funds, Obesity Start-ups and More

Lately, it appears some biotech VCs have hit a ceiling, capping their new funds at or below the amount of their previous vehicles, says Paul Bonanos on the latest BioCentury This Week. Bonanos and his BioCentury editorial colleagues discuss what’s behind the trend as they assess VC fundraising in this post-‘supercycle’ era. The editors also evaluate the state of play for venture-backed obesity plays and which VCs are active in the space, as well as takeaways from the latest BioCentury Show po...

1 month ago

33 minutes

BioCentury This Week

Ep. 268 - Biosecure Setback & Novartis' $1B PTC Deal

A pair of lawmakers have dealt the Biosecure Act a setback that could derail the legislation, even as Congress continues its push to reduce reliance on China in the life sciences. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin explains why Sen. Rand Paul (R-Ky.) and Rep. Jamie Raskin (D-Md.) refused to sign off on inclusion of the anti-China biotech bill in the must-pass National Defense Authorization Act, what provisions the defense bill has that seek to enhance U....

1 month ago

21 minutes

BioCentury This Week

Ep. 267 - Trump's NIH Pick & Multi-targeted CAR Ts

On the latest BioCentury This Week podcast, Washington Editor Steve Usdin and colleagues discuss how President-elect Donald Trump’s pick to lead NIH, Jay Bhattacharya, would lead NIH and how that could affect the biopharma industry. The BioCentury team then discusses its analysis of abstracts released ahead of the American Society of Hematology (ASH) and Society for Immunotherapy of Cancer (SITC) annual conferences, highlighting methods for applying dual or bispecific CAR T cell designs to so...

2 months ago

27 minutes

BioCentury This Week

Ep. 266 - Jefferies Recap, FDA Commissioner & Biosecure Update

Positive vibes about biotech emanating from the Jefferies Healthcare Conference were overshadowed by the uncertainty that is ahead because of the result of the U.S. elections. On the latest BioCentury This Week, BioCentury’s editors discuss how the unconventional cabinet nominations of the incoming Trump administration have cast a pall over what had been growing enthusiasm for the prospects of the biotech sector. Washington Editor Steve Usdin also discusses what the nomination of Marty Makary...

2 months ago

26 minutes

BioCentury This Week

Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals

Giving RFK Jr. control of HHS would be disastrous, argues Washington Editor Steve Usdin on the latest BioCentury This Week podcast. Expanding on his Editor’s Commentary, Usdin explains why Kennedy would be an unmitigated disaster for FDA, NIH and CMS, for biopharmas and for patients. He calls on biopharma leaders to speak out and affirm basic truths, even if it puts them in harm’s way. BioCentury’s editors also discuss why new data for GSK's Blenrep — an oncology therapy withdrawn two years a...

2 months ago

29 minutes

BioCentury This Week

Ep. 264 - Prepping for Trump & Alzheimer's Ethics

Trump 2.0 presents opportunities and challenges for leaders of the biopharma industry, which needs effective public policy to thrive. On the latest BioCentury This Week, BioCentury Washington Editor Steve Usdin explains what those opportunities are and lays out the potential impact on the public policy environment, which could have repercussions on FDA and beyond. BioCentury’s editors then analyze how companies, academics and advocates are pushing back on claims that they should have disclose...

2 months ago

29 minutes

BioCentury This Week

Ep. 263 - Alzheimer Insights: Anti-Amyloid Safety & Tau Teaser

It’s too soon to conclude anti-amyloid therapies are safe for use by Alzheimer’s patients in the real world, even as early reports are encouraging, argues BioCentury Executive Editor Selina Koch on the latest BioCentury This Week podcast. Koch and colleagues discuss takeaways from this year’s Clinical Trials on Alzheimer’s Disease annual meeting, including conclusions from adverse event data for Leqembi lecanemab and what the true test of appropriate use and safety for the drug might look lik...

3 months ago

34 minutes

BioCentury This Week

Ep. 262 - EGFR Case Study, FDA & Politics

Twenty years of innovation in therapies targeting EGFR provides a case study in how generation of differentiated products against the target can drive market growth. On the latest BioCentury This Week podcast, BioCentury’s editors discuss EGFR as a prime example of the value in best-in-class development strategies, with meaningful improvements across multiple modalities delivering substantial therapeutic benefits to patients. Analogous best-in-class opportunities aren’t limited to cancer, but...

3 months ago

23 minutes

BioCentury This Week

Ep. 261 - China Summit: Reinventing Your China Strategy

Cross-border geopolitical tensions and a prolonged capital crunch are compelling biopharma companies from Beijing to Boston to rethink their strategies on everything from deal-making and raising capital to manufacturing and use of CROs. On a special edition of the BioCentury This Week podcast, McKinsey’s Franck Le Deu and Wendy Pan of BayHelix and Goodwin join BioCentury on the eve of next week’s eleventh annual BioCentury-BayHelix China Healthcare Summit in Shanghai to discuss the dynamics a...

3 months ago

31 minutes

BioCentury This Week

Ep. 260 - VC Funds, New Chapter for MS, Wave's Data

At least 25 venture firms have raised a total of more than $17 billion in funds this year, with Forbion unveiling the largest-ever European biopharma fund at €1.2 billion last week. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how Forbion deployed its prior fund and quickly raised fresh funds and what that — and other funds — say about the state of financing private biotechs in Europe and elsewhere. The editors then assess takeaways from BioCentury’s conversation w...

3 months ago

31 minutes

BioCentury This Week

Ep. 259 - Causal Biology and Big Data, Ultra-Rare Drugs at FDA

There is a growing mandate among researchers and VCs to provide proof of causal human biology for new targets. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the different strategies being deployed to identify causal links to disease using observational patient data or human cell models, including the challenges that come with each approach and the various computational methodologies companies are using. They also discuss the outcome of FDA’s advisory committee meeti...

3 months ago

33 minutes